A pilot study to evaluate the safety and efficacy of the long‐acting interleukin‐1 inhibitor rilonacept (interleukin‐1 trap) in patients with familial cold autoinflammatory syndrome

Objective Familial cold autoinflammatory syndrome (FCAS) is caused by mutations in the CIAS1 gene, leading to excessive secretion of interleukin‐1β (IL‐1β), which is associated with cold‐induced fevers, joint pain, and systemic inflammation. This pilot study was conducted to assess the safety and efficacy of rilonacept (IL‐1 Trap), a long‐acting IL‐1 receptor fusion protein, in patients with FCAS. Methods Five patients with FCAS were studied in...